中国人群青光眼筛查的成本效果与成本效用:决策分析马尔可夫模型
研究采用决策分析马尔可夫模型,从社会角度评估中国社区水平筛查原发性闭角型青光眼(PACG)和原发性开角型青光眼(POAG)与机会性病例发现相比的成本与效益。模型对50岁队列随访30个1年周期,分农村和城市分析。结果显示联合筛查在农村ICUR为569美元(95%CI 17-4180)、ICER为1280美元(-58-7940),低于WHO成本效果阈值;城市联合筛查净成本更低且健康收益更高。结论认为联合筛查在中国城乡均可能具有成本效果。
要点
- 农村联合筛查ICUR为569美元,低于WHO成本效果阈值。
- 城市联合筛查较不筛查净成本更低且健康收益更高。
- 每10万农村和城市居民筛查30年分别避免246和1325年盲。
核心结论
- 中国城乡人群联合筛查POAG和PACG可能具有成本效果。
研究设计与样本
- 决策分析马尔可夫模型,分农村和城市设置,50岁队列随访30个1年周期。
- 比较社区水平筛查与机会性病例发现,从社会角度分析。
- 对PACG和POAG分别及联合筛查建模,筛查成本取自中国筛查项目,治疗成本取自中国三甲眼科医院。
主要发现
- 农村联合筛查对比不筛查:ICUR为569美元(95%CI 17-4180),ICER为1280美元(-58-7940)。
- 城市联合筛查对比不筛查:净成本更低且健康收益更高。
- 每10万农村居民筛查30年避免246年盲(95%CI 63-628)。
- 每10万城市居民筛查30年避免1325年盲(95%CI 510-2828)。
- 所有敏感性分析结果稳健。
关键数值与推荐
- 农村联合筛查ICUR和ICER均低于WHO成本效果阈值(农村GDP的1-3倍)。
临床怎么用
- 可考虑在中国城乡开展POAG和PACG联合人群筛查。
- 未来需研究提高筛查后接受确定性治疗依从性的干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glaucoma, particularly primary angle closure glaucoma (PACG), is a leading cause of global blindness. Nearly half of all people with PACG are of Chinese descent. Population-level glaucoma screening has generally not been found to be cost-effective in high-income countries; however, this assessment has rarely been done in low-income or middle-income countries. We aimed to assess the cost-effectiveness and cost-utility of population-level glaucoma screening in China. METHODS: We developed decision-analytic Markov models for separate and combined screening for PACG and primary open angle glaucoma (POAG) to evaluate costs and benefits of community-level screening versus opportunistic case finding from a societal perspective. A cohort of individuals was followed in the model from age 50 years through a total of 30 1-year Markov cycles. Analyses were done separately for rural and urban settings. We did a meta-analysis of glaucoma prevalence studies in China to obtain prevalence estimates for PACG and POAG. Screening costs were taken from a Chinese screening programme and treatment costs from a tertiary Chinese eye hospital. Main outcomes were incremental cost-utility ratios (ICURs) using quality-adjusted life-years and incremental cost-effectiveness ratios (ICERs) using years of blindness avoided. We did one-way deterministic and simulated probabilistic sensitivity analyses to reflect uncertainty around ICURs and ICERs. FINDINGS: Compared with no screening, combined screening of POAG and PACG in rural China is predicted to result in an ICUR of US$569 (95% CI 17 to 4180) and an ICER of $1280 (-58 to 7940), both of which are below the WHO cost-effectiveness threshold of one to three times rural gross domestic product. For the urban China setting, combined screening is predicted to result in fewer net costs and greater gain in health benefits than no screening. Findings were robust in all sensitivity analyses. Over 30 years, a total of 246 (95% CI 63 to 628) and 1325 (510 to 2828) years of blindness are predicted to be avoided for every 100 000 rural and urban residents screened, respectively. INTERPRETATION: Population screening for glaucoma (POAG and PACG combined) is likely to be cost-effective in both urban and rural China. Future studies should investigate the effectiveness of interventions to improve acceptance of definitive care among people screened. FUNDING: Ulverscroft Foundation, Wenzhou Medical University Research Fund, Zhejiang Province Health Innovation Talents Project, and Wenzhou's Ten Major Livelihood Issues 2015.
引用
- Tang J, Liang Y, O'Neill C, et al. Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model. Lancet Glob Health. 2019. PMID: 31122906. doi:10.1016/S2214-109X(19)30201-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。